Synergy Pharmaceuticals Inc (PINK:SGYP) has been falling down progressively since last Friday. Yesterday, the stock lost 
another 21.15% of its price, while its traded volume notably increased. However, the reason for the fall is still unknown.
Historical records show that Synergy has not released any news on its activities lately, thus no one is familiar with them. Yet, the last data about the company is a document filed with the SEC stating that the business of SGYP and an investment in their securities involves a high degree of risk as explained in the prospect. Among the risk factors appear to be significant losses, expensive clinical trials, missing FDA approval, etc.
These risk factors have certainly discouraged traders even more than the lack of recent news on SGYP, which can easily explain its unstable chart position.
Synergy Pharmaceuticals, Inc is a development-stage biopharmaceutical company focused on drugs to treat gastrointestinal conditions and diseases. Despite the missing news these days, the company is still trading at over $2.00 per share.
However, in May the stock price was more than 50% higher as compared to present.[BANNER]
Regarding the latest 10-Q report of SGYP, the situation doesn’t look better at all. Missing revenues, a shocking accumulated deficit, over $12 million in liabilities and stockholders’ deficit exceeding $10 million.
Having in mind the other losses, as well as the risk factors, Synergy’s financial condition turns out to be completely disastrous. Meaning that if they don’t find additional capital, its future operation might be rather doubtful.
